Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · Real-Time Price · USD
27.80
+0.25 (0.91%)
At close: Mar 13, 2026, 4:00 PM EDT
27.80
0.00 (0.00%)
After-hours: Mar 13, 2026, 7:57 PM EDT
Travere Therapeutics Stock Forecast
Stock Price Forecast
The 12 analysts that cover Travere Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $36.25, which forecasts a 30.40% increase in the stock price over the next year. The lowest target is $25 and the highest is $47.
Price Target: $36.25 (+30.40%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Feb 6, 2026.
Analyst Ratings
The average analyst rating for Travere Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Buy | 7 | 6 | 6 | 6 | 6 | 4 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 15 | 15 | 15 | 15 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Hold Maintains $35 → $38 | Hold | Maintains | $35 → $38 | +36.69% | Feb 6, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $47 | Strong Buy | Reiterates | $47 | +69.06% | Nov 28, 2025 |
| Piper Sandler | Piper Sandler | Hold Maintains $26 → $35 | Hold | Maintains | $26 → $35 | +25.90% | Nov 4, 2025 |
| TD Cowen | TD Cowen | Strong Buy Maintains $30 → $40 | Strong Buy | Maintains | $30 → $40 | +43.88% | Oct 31, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $47 | Strong Buy | Reiterates | $47 | +69.06% | Sep 19, 2025 |
Financial Forecast
Revenue This Year
709.71M
from 490.73M
Increased by 44.62%
Revenue Next Year
937.49M
from 709.71M
Increased by 32.09%
EPS This Year
0.29
from -0.29
EPS Next Year
2.06
from 0.29
Increased by 617.68%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 948.5M | 1.2B | |||
| Avg | 709.7M | 937.5M | |||
| Low | 575.3M | 660.2M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 93.3% | 73.3% | |||
| Avg | 44.6% | 32.1% | |||
| Low | 17.2% | -7.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 1.48 | 6.26 | |||
| Avg | 0.29 | 2.06 | |||
| Low | -0.64 | 0.47 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | 2,083.4% | |||
| Avg | - | 617.7% | |||
| Low | - | 64.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.